April 28, 2021

A Randomised Clinical Trial of Azithromycin versus Standard Care in Ambulatory COVID-19 – the ATOMIC2 Trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• [Pre-print, not peer-reviewed] In a 1:1 randomized open-label trial among ambulatory patients with mild-moderate COVID-19 in the UK (n=292), those randomized to receive the antibiotic azithromycin had no significance difference in death or hospitalization within 28 days compared to patients receiving standard care (OR=0.91, 95% CI: 0.43-1.92). Rates of respiratory failure, progression to pneumonia, all-cause mortality, and adverse events, including serious cardiovascular events, were not significantly different between groups.

Hinks et al. (Apr 27, 2021). A Randomised Clinical Trial of Azithromycin versus Standard Care in Ambulatory COVID-19 – the ATOMIC2 Trial. Pre-print downloaded Apr 28 from https://doi.org/10.1101/2021.04.21.21255807